223 related articles for article (PubMed ID: 37296748)
1. Homologous Recombination Deficiency Score Determined by Genomic Instability in a Romanian Cohort.
Rădoi VE; Țurcan M; Maioru OV; Dan A; Bohîlțea LC; Dumitrescu EA; Gheorghe AS; Stănculeanu DL; Thodi G; Loukas YL; Săbău ID
Diagnostics (Basel); 2023 May; 13(11):. PubMed ID: 37296748
[TBL] [Abstract][Full Text] [Related]
2. Clinical assays for assessment of homologous recombination DNA repair deficiency.
Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF
Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552
[TBL] [Abstract][Full Text] [Related]
3. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
[TBL] [Abstract][Full Text] [Related]
4. Concordance between single-nucleotide polymorphism-based genomic instability assays and a next-generation sequencing-based homologous recombination deficiency test.
Cristescu R; Liu XQ; Arreaza G; Chen C; Albright A; Qiu P; Marton MJ
BMC Cancer; 2022 Dec; 22(1):1310. PubMed ID: 36517748
[TBL] [Abstract][Full Text] [Related]
5. Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.
Lotan TL; Kaur HB; Salles DC; Murali S; Schaeffer EM; Lanchbury JS; Isaacs WB; Brown R; Richardson AL; Cussenot O; Cancel-Tassin G; Timms KM; Antonarakis ES
Mod Pathol; 2021 Jun; 34(6):1185-1193. PubMed ID: 33462368
[TBL] [Abstract][Full Text] [Related]
6. In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay.
Fumagalli C; Betella I; Ranghiero A; Guerini-Rocco E; Bonaldo G; Rappa A; Vacirca D; Colombo N; Barberis M
Pathologica; 2022 Aug; 114(4):288-294. PubMed ID: 36136896
[TBL] [Abstract][Full Text] [Related]
7. Prediction of homologous recombination deficiency from Oncomine Comprehensive Assay Plus correlating with SOPHiA DDM HRD Solution.
Kang J; Na K; Kang H; Cho U; Kwon SY; Hwang S; Lee A
PLoS One; 2024; 19(3):e0298128. PubMed ID: 38527014
[TBL] [Abstract][Full Text] [Related]
8. Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer.
Wen H; Feng Z; Ma Y; Liu R; Ou Q; Guo Q; Shen Y; Wu X; Shao Y; Bao H; Wu X
BMC Cancer; 2022 May; 22(1):550. PubMed ID: 35578198
[TBL] [Abstract][Full Text] [Related]
9. Optical Genome Mapping: Integrating Structural Variations for Precise Homologous Recombination Deficiency Score Calculation.
Sahajpal NS; Mondal AK; Vashisht A; Singh H; Pang AWC; Saul D; Nivin O; Hilton B; DuPont BR; Kota V; Savage NM; Hastie AR; Chaubey A; Kolhe R
Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761823
[TBL] [Abstract][Full Text] [Related]
10. Homologous recombination deficiency (HRD) testing on cell-free tumor DNA from peritoneal fluid.
Roussel-Simonin C; Blanc-Durand F; Tang R; Vasseur D; Le Formal A; Chardin L; Yaniz E; Gouy S; Maulard A; Scherier S; Sanson C; Lacroix L; Cotteret S; Mauny L; Zaccarini F; Rouleau E; Leary A
Mol Cancer; 2023 Nov; 22(1):178. PubMed ID: 37932736
[TBL] [Abstract][Full Text] [Related]
11. Potential value of the homologous recombination deficiency signature we developed in the prognosis and drug sensitivity of gastric cancer.
Wu X; Wang Q; Liu P; Sun L; Wang Y
Front Genet; 2022; 13():1026871. PubMed ID: 36468004
[No Abstract] [Full Text] [Related]
12. Direct prediction of Homologous Recombination Deficiency from routine histology in ten different tumor types with attention-based Multiple Instance Learning: a development and validation study.
Loeffler CML; El Nahhas OSM; Muti HS; Seibel T; Cifci D; van Treeck M; Gustav M; Carrero ZI; Gaisa NT; Lehmann KV; Leary A; Selenica P; Reis-Filho JS; Bruechle NO; Kather JN
medRxiv; 2023 Mar; ():. PubMed ID: 36945540
[TBL] [Abstract][Full Text] [Related]
13. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
[TBL] [Abstract][Full Text] [Related]
14. Targeting homologous recombination deficiency in uterine leiomyosarcoma.
Dall G; Vandenberg CJ; Nesic K; Ratnayake G; Zhu W; Vissers JHA; Bedő J; Penington J; Wakefield MJ; Kee D; Carmagnac A; Lim R; Shield-Artin K; Milesi B; Lobley A; Kyran EL; O'Grady E; Tram J; Zhou W; Nugawela D; Stewart KP; Caldwell R; Papadopoulos L; Ng AP; Dobrovic A; Fox SB; McNally O; Power JD; Meniawy T; Tan TH; Collins IM; Klein O; Barnett S; Olesen I; Hamilton A; Hofmann O; Grimmond S; Papenfuss AT; Scott CL; Barker HE
J Exp Clin Cancer Res; 2023 May; 42(1):112. PubMed ID: 37143137
[TBL] [Abstract][Full Text] [Related]
15. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Telli ML; Timms KM; Reid J; Hennessy B; Mills GB; Jensen KC; Szallasi Z; Barry WT; Winer EP; Tung NM; Isakoff SJ; Ryan PD; Greene-Colozzi A; Gutin A; Sangale Z; Iliev D; Neff C; Abkevich V; Jones JT; Lanchbury JS; Hartman AR; Garber JE; Ford JM; Silver DP; Richardson AL
Clin Cancer Res; 2016 Aug; 22(15):3764-73. PubMed ID: 26957554
[TBL] [Abstract][Full Text] [Related]
16. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
Swisher EM; Aghajanian C; O'Malley DM; Fleming GF; Kaufmann SH; Levine DA; Birrer MJ; Moore KN; Spirtos NM; Shahin MS; Reid TJ; Friedlander M; Steffensen KD; Okamoto A; Sehgal V; Ansell PJ; Dinh MH; Bookman MA; Coleman RL
Gynecol Oncol; 2022 Feb; 164(2):245-253. PubMed ID: 34906376
[TBL] [Abstract][Full Text] [Related]
17. Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.
Pujade-Lauraine E; Brown J; Barnicle A; Wessen J; Lao-Sirieix P; Criscione SW; du Bois A; Lorusso D; Romero I; Petru E; Yoshida H; Vergote I; Colombo N; Hietanen S; Provansal M; Schmalfeldt B; Pignata S; Martín Lorente C; Berton D; Runnebaum IB; Ray-Coquard I
JCO Precis Oncol; 2023 Jan; 7():e2200258. PubMed ID: 36716415
[TBL] [Abstract][Full Text] [Related]
18. Homologous recombination deficiency real-time clinical assays, ready or not?
Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
[TBL] [Abstract][Full Text] [Related]
19. Biomarker Assessment of Homologous Recombination Deficiency in Epithelial Ovarian Cancer: Association With Progression-Free Survival After Surgery.
Yi H; Li L; Huang J; Ma Z; Li H; Chen J; Zheng X; Chen J; He H; Song J
Front Mol Biosci; 2022; 9():906922. PubMed ID: 35769916
[TBL] [Abstract][Full Text] [Related]
20. Biomarker Assessment of HR Deficiency, Tumor
Stronach EA; Paul J; Timms KM; Hughes E; Brown K; Neff C; Perry M; Gutin A; El-Bahrawy M; Steel JH; Liu X; Lewsley LA; Siddiqui N; Gabra H; Lanchbury JS; Brown R
Mol Cancer Res; 2018 Jul; 16(7):1103-1111. PubMed ID: 29724815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]